Abstracts tagged "osteoarthritis and treatment options"

Abstract Number: 439 • 2018 ACR/ARHP Annual Meeting
Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18)
Ditte Reker¹, Christian S. Thudium², Anne Sofie Siebuhr³, Thorbjørn Gantzel⁴, Christoph Ladel⁵, Martin Michaelis⁵, Morten A. Karsdal², Anne Gigout⁵ and Anne C. Bay-Jensen², ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴cOrthopedic Surgery Unit, Gentofte Hospital, Hellerup, Denmark, ⁵Merck KGaA, Darmstadt, Germany
Background/Purpose: Sprifermin, a truncated form of human fibroblast growth factor 18 (FGF18), is being investigated as a potential cartilage and disease-modifying OA drug. In vitro,…
Abstract Number: 311 • 2015 ACR/ARHP Annual Meeting
Comparison Between Intra Articular Ozone and Placebo in the Treatment of Knee Osteoarthritis: A Multicentric, Comparative, Randomized and Double-Blinded Clinical Trial
Carlos Jesus¹, Virginia Trevisani^2,3 and Fânia Santos⁴, ¹Health Evidence Based, Escola Paulista de Medicina - Universidade Federal de São Paulo, São Paulo, Brazil, ²Health Evidence Based, Universidade Federal de São Paulo, Sâo Paulo, Brazil, ³Health Evidence Based, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Geriatrics and Gerontology Departament, Escola Paulista de Medicina - Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Osteoarthritis (OA) is a common, progressive condition, which is associated with severe pain, functional disability and impairment of health related quality of life, causing…
Abstract Number: 2139 • 2013 ACR/ARHP Annual Meeting
Do Hyaluronic Acid Injections Delay Total Knee Replacement Surgery?
Thomas Abbott¹, Roy D. Altman², Robert Dimeff³, Michael Fredericson⁴, Vijay Vad⁵, Peter Vitanzo Jr.⁶, Sashi Yadalam¹, Ronald Levine¹, Brad Bisson⁷ and Samir Bhattacharyya⁷, ¹Johnson & Johnson, New Brunswick, NJ, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Stanford University School of Medicine, Menlo Park, CA, ⁵Weill Cornell Medical College, NY, NY, ⁶Rothman Institute, Philadelphia, PA, ⁷DePuy Synthes Mitek Sports Medicine, Raynham, MA
Background/Purpose: More than 27 million adults in the US have knee osteoarthritis (OA), a painful and life-altering disease. Various non-pharmacologic and pharmacologic agents are recommended…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].